ONYX BIOTEC LIMITED IPO Review
Neutral61-61 · SME
✦
Analyst Verdict
ONYX BIOTEC LIMITED IPO
Neutral
IPO at a Glance
Price Band
61-61
Issue Size
29cr
Min. Investment
₹1,22,000
Opens
2024-11-11
Closes
2024-11-16
Listing
2024-11-20
Category
SME
Key Strengths
✓Leading contract manufacturer specializing in sterile pharmaceutical production.
✓Rigorous Quality Assurance and Quality Control processes ensure high product standards.
✓Established, long-term relationships with top-tier clients in the pharmaceutical industry.
✓Cost-efficient production processes with a focus on timely order fulfilment.
✓Experienced management team with strong project management and implementation expertise.
Key Risks
⚠Region-specific risks in Solan, Himachal Pradesh could impact operations.
⚠Manufacturing disruptions could harm financial health and cash flow.
⚠Reliance on third-party suppliers risks supply delays or shortages.
⚠Heavy dependence on key clients makes revenue vulnerable to client loss.
⚠Pharmaceutical industry downturns could reduce demand for products.
⚠Quality or delivery issues may lead to order cancellations and financial loss.
Frequently Asked Questions
Should I apply for ONYX BIOTEC LIMITED IPO?
Based on our analysis, our rating for ONYX BIOTEC LIMITED IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of ONYX BIOTEC LIMITED IPO?
Region-specific risks in Solan, Himachal Pradesh could impact operations. Manufacturing disruptions could harm financial health and cash flow. Reliance on third-party suppliers risks supply delays or shortages.
What are the strengths of ONYX BIOTEC LIMITED IPO?
Leading contract manufacturer specializing in sterile pharmaceutical production. Rigorous Quality Assurance and Quality Control processes ensure high product standards. Established, long-term relationships with top-tier clients in the pharmaceutical industry.
What is the price band of ONYX BIOTEC LIMITED IPO?
The price band for ONYX BIOTEC LIMITED IPO is 61-61. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more